Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating

Psychopharmacology

Volumn 231, Issue 10, 2014, Pages 2189-2197

  Gresack, Jodi E ^a,e   Seymour, Patricia A ^b,c   Schmidt, Christopher J ^b   Risbrough, Victoria B ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PFIZER INC   (United States)

^c Mnemosyne Pharmaceuticals Inc   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Acoustic startle; Apomorphine; PDE10A; Phosphodiesterase inhibitor; Prepulse inhibition; Quinpirole; Rat; SCH23390

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; ENZYME INHIBITOR; HALOPERIDOL; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; PHOSPHODIESTERASE 10A INHIBITOR; UNCLASSIFIED DRUG; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; BENZAZEPINE DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; PDE10A PROTEIN, RAT; PHOSPHODIESTERASE INHIBITOR; QUINPIROLE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SENSORY GATING; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; DRUG EFFECTS; METABOLISM; SPRAGUE DAWLEY RAT; STARTLE REFLEX;

ANIMALS; APOMORPHINE; BENZAZEPINES; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; MALE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; QUINPIROLE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; REFLEX, STARTLE; SENSORY GATING; SIGNAL TRANSDUCTION;

EID: 84900850648     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3371-7     Document Type: Article

References (48)

1. Agid O, Kapur S, Remington G (2008) Emerging drugs for schizophrenia. Expert Opin Emerg Drugs 13:479-495
2. Bleickardt C, LaShomb A, Jones N, Mullins D, Uslaner J, Vardigan J et al. (2010) Characterization of the selective PDE10 inhibitor, SCH 1518291, in rodent models predictive of antipsychotic efficacy. Program Number 665.15. 2010 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2010. Online
3. Bortolato M, Aru GN, Fà M, Frau R, Orrù M, Salis P et al (2005) Activation of D1, but not D2 receptors potentiates dizocilpine-mediated disruption of prepulse inhibition of the startle. Neuropsychopharmacology 30:561-574
4. Braff DL, Geyer MA, Swerdlow NR (2001) Human studies of prepulse inhibition of startle: normal subjects, patients groups, and pharmacological studies. Psychopharmacology 156:234-258
5. Bubenikova-Valesova V, Svoboda J, Horacek J, Vales K (2009) The effect of a full agonist/antagonist of the D1 receptor on locomotor activity, sensorimotor gating and cognitive function in dizocilpine-treated rats. Int J Neuropsychopharmacol 12:873-883
6. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence. Annu Rev Pharmacol Toxicol 41:237-260
7. Chang WL, Weber M, Breier MR, Saint Marie RL, Hines SR, Swerdlow NR (2012) Stereochemical and neuroanatomical selectivity of pramipexole effects on sensorimotor gating in rats. Brain Res 1437:69-76
8. Chappie T, Humphrey J, Menniti F, Schmidt C (2009) PDE10A inhibitors: an assessment of the current CNS drug discovery landscape. Curr Opin Drug Discov Dev 12:458-467
9. DeMartinis NA (2012) Results of a phase 2a proof-of-concept trial with a PDE10A inhibitor in the treatment of acute exacerbation of schizophrenia. Session 16, Presentation Number 62. 2012 Meeting Planner. Philadelphia, PA: Society of Biological Psychiatry, 2012. Online
10. Ellenbroek BA, Budde S, Cools AR (1996) Prepulse inhibition and latent inhibition: the role of dopamine in the medial prefrontal cortex. Neuroscience 75:535
11. Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K (1999) Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 274:18438-18445
12. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156:117-154
13. Goff DC, Coyle JT (2001) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158:1367-1377
14. Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R et al (2009) Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther 331:574-590
15. Hoffman DC, Donovan H (1994) D1 and D2 dopamine receptor antagonists reverse prepulse inhibition deficits in an animal model of schizophrenia. Psychopharmacology 115:447-453
16. Kapur S, Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27:1081-1090
17. Kehler J, Nielsen J (2011) PDE10A inhibitors: novel therapeutic drugs for schizophrenia. Curr Pharm Des 17:137-150
18. Matamales M, Bertran-Gonzalez J, Salomon L, Degos B, Deniau JM, Valjent E et al (2009) Striatal medium-sized spiny neurons: identification by nuclear staining and study of neuronal subpopulations in BAC transgenic mice. PLoS One 4:e4770
19. McClure MM, Harvey PD, Goodman M, Triebwasser J, New A, Koenigsberg HW et al (2010) Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum. Neuropsychopharmacology 35:1356-1362
20. Menniti FS, Faraci WS, Schmidt CJ (2006) Phosphodiesterases in the CNS: targets for drug development. Nat Rev 5:660-670
21. Menniti FS, Chappie TA, Humphrey JM, Schmidt CJ (2007) Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs 8:54-59
22. Natesan S, Reckless GE, Barlow KB, Odontiadis J, Nobrega JN, Baker GB et al (2008) The antipsychotic potential of l-stepholidine - a naturally occurring dopamine receptor D1 agonist and D2 antagonist. Psychopharmacology 199:275-289
23. Nishi A, Kuroiwa M, Miller DB, O'Callaghan JP, Bateup HS, Shuto T (2008) Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci 28:10460-10471
24. Nishi A, Kuroiwa M, Shuto T (2011) Mechanisms for the modulation of dopamine D1 receptor signaling in striatal neurons. Front Neuroanat 5:1-10
25. O'Donnell P, Grace AA (1998) Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters. Schizophr Bull 24:267-283
26. Ouagazzal AM, Jenck F, Moreau JL (2001) Drug-induced potentiation of prepulse inhibition of acoustic startle reflex in mice: a model for detecting antipsychotic activity? Psychopharmacology 156:273-283
27. Peng RY, Mansbach RS, Braff DL, Geyer MA (1990) A D2 dopamine receptor agonist disrupts sensorimotor gating in rats. Implications for dopaminergic abnormalities in schizophrenia. Neuropsychopharmacology 3:211-218
28. Ralph RJ, Caine SB (2005) Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6 J, and DBA/2 J mice. J Pharmacol Exp Ther 312:733-741
29. Ralph-Williams RJ, Lehmann-Masten V, Otero-Corchon V, Low MJ, Geyer MA (2002) Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice. J Neurosci 22:9604-9611
30. Roberts BM, Seymour PA, Schmidt CJ, Williams GV, Castner SA (2010) Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists. Psychopharmacology 210:407-418
31. Rodefer J, Murphy ER, Baxter MG (2005) PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci 21:1070-1076
32. Sano H, Nagai Y, Miyakawa T, Shigemoto R, Yokoi M (2008) Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase10A2. J Neurochem 105:546-556
33. Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF et al (2008) Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 325:681-690
34. Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL et al (2003) Immunohistochemical localization of PDE10A in the rat brain. Brain Res 985:113-126
35. Simpson EH, Kellendonk C, Kandel E (2010) A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 65:585-596
36. Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L et al (2006) Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 51:386-396
37. Smith SM, Uslaner JM, Cox CD, Huszar SL, Cannon CE, Vardigan JD et al (2013) The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Neuropharmacology 64:215-223
38. Sotty F, Montezinho LP, Steiniger-Brach B, Nielsen J (2009) Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to d-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons. J Neurochem 109:766-805
39. Stevenson CW, Gratton A (2004) Role of basolateral amygdala dopamine in modulating prepulse inhibition and latent inhibition in the rat. Psychopharmacology 176:139-145
40. Strick CA, James LC, Fox CB, Seeger TF, Menniti FS, Schmidt CJ (2010) Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A. Neuropharmacology 58:444-451
41. Surmeier D, Ding J, Day M, Wang Z, Shen W (2007) D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 30:228-235
42. Swerdlow NR, Keith VA, Braff DL, Geyer MA (1991) Effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rat. J Pharmacol Exp Ther 256:530-536
43. Swerdlow NR, Shoemaker JM, Bongiovanni MJ, Neary AC, Tochen LS, Saint Marie RL (2005) Reduced startle gating after D1 blockade: effects of concurrent D2 blockade. Pharmacol Biochem Behav 82:293-299
44. Swerdlow NR, Shoemaker JM, Kuczenski R, Bongiovanni MJ, Neary AC, Tochen LS et al (2006) Forebrain D1 function and sensorimotor gating in rats: effects of D1 blockade, frontal lesions and dopamine denervation. Neurosci Lett 402:40-45
45. Swerdlow NR, Weber M, Qu Y, Light GA, Braff DL (2008) Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology 199:331-388
46. Wan FJ, Taaid N, Swerdlow NR (1996) Do D1/D2 interactions regulate prepulse inhibition in rats? Neuropsychopharmacology 14:265-274
47. Weber M, Breier M, Ko D, Thangaraj N, Marzan DE, Swerdlow NR (2009) Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine. Psychopharmacology 203:723-735
48. Young JW, Powell SB, Geyer MA (2012) Mouse pharmacological models of cognitive disruption relevant to schizophrenia. Neuropharmacology 62:1381-1390